Preparation method of collagen hydrogel
By pre-crosslinking collagen with NHS and EDC and then immersing it in ethanol, a stable and aesthetically effective collagen hydrogel is produced, addressing the limitations of existing collagen products.
Patent Information
- Application Number
- CN202411227878.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-03
- Publication Date
- 2024-12-06
AI Technical Summary
Current collagen products for medical aesthetics suffer from poor stability and limited functionality, failing to meet the diverse needs of consumers beyond simple filling purposes.
A method involving pre-crosslinking collagen with N-hydroxysuccinimide (NHS) and 1-ethyl-(3-dimethylaminopropyl)carbodiimide (EDC) followed by immersion in ethanol or an ethanol solution to achieve complete cross-linking, resulting in a milky white collagen hydrogel with enhanced stability and aesthetic filling effects.
The prepared collagen hydrogel exhibits excellent stability and a concealing effect, making it suitable for long-term medical and aesthetic applications.
Smart Images

Figure SMS_2 
Figure SMS_3 
Figure SMS_4
Abstract
Description
Technical Field
[0001] The present application relates to the technical field of hydrogels for medical aesthetics, and further to a method for preparing collagen hydrogels. Background Art
[0002] With the development of the medical beauty industry, medical beauty injection products have received increasing attention from the market. So far, many products have been launched and recognized by the market. Medical beauty injection products with hyaluronic acid, collagen, regenerative agents, botulinum toxin, exosomes, etc. as raw materials are favored by companies and consumers. Thanks to the market growth and the improvement of the industrial chain, medical beauty injection products have shown a diversified development trend. Not only are there continuous innovations in raw materials, equipment, production processes, etc., but there are also many explorations in the use methods and the combined application of multiple materials.
[0003] Shuangmei Biotechnology's porcine collagen product is the earliest product of collagen medical aesthetic injection to be launched in China, developed based on the American bovine collagen extraction process. Artevo from Hanford Biotech in the Netherlands, whose product contains 20% polymethyl methacrylate (PMMA) microspheres, was generally considered a semi-permanent injection material in the market when it was launched in 2002. Since then, domestic collagen medical aesthetic injection products have been launched one after another, mostly from animal sources.
[0004] In 2021, Jinbo Bio's Weiyimei was successfully approved, becoming China's first recombinant collagen product for medical aesthetic injections, setting off a craze for recombinant collagen injections. Recombinant collagen companies represented by Juzi Bio, Juyuan Bio, and Chuangjian Medical are also stepping up registration applications for collagen medical aesthetic injection products.
[0005] As consumers' understanding of the medical beauty field continues to deepen, their needs will become more diversified. The current implant products that are only for filling purposes can no longer meet people's growing needs. The current collagen products also have the problem of poor stability, which in turn affects the product effect. Therefore, it is urgent to develop a product that can provide both filling and high stability. Summary of the invention
[0006] The present application provides a method for preparing a collagen hydrogel. In the method, when the collagen is not completely cross-linked, it is immersed in ethanol or an ethanol solution until it is completely cross-linked; the collagen hydrogel finally obtained is milky white and can have a good concealing effect when used for medical and aesthetic filling; in addition, the collagen hydrogel has excellent stability.
[0007] This application involves the following:
[0008] 1. A method for preparing a collagen hydrogel, comprising the following steps:
[0009] Mixing the collagen and the cross-linking agent evenly in the solution to obtain a pre-cross-linked hydrogel mixture;
[0010] The pre-crosslinked hydrogel mixture is immersed in an ethanol solvent and mixed evenly, and then allowed to stand and soak for at least 2 hours to obtain a completely crosslinked collagen hydrogel;
[0011] The cross-linking agents are N-hydroxysuccinimide (NHS) and 1-ethyl-(3-dimethylaminopropyl)carbodiimide (EDC);
[0012] The ethanol solvent is ethanol or an ethanol solution comprising ethanol and water, wherein the volume proportion of ethanol in the ethanol solution is 70-99.99 Vol.%;
[0013] Preferably, the volume percentage of ethanol in the ethanol solution is 80-99.99 Vol.%;
[0014] Preferably, the ethanol solvent is ethanol;
[0015] Preferably, the standing soaking time is 2-8 hours.
[0016] 2. In the preparation method described in item 1, when the collagen and the cross-linking agent are mixed evenly, NHS and EDC are added together and then mixed evenly, or NHS is added first and mixed evenly and then EDC is added and mixed evenly.
[0017] 3. In the preparation method described in item 2, after NHS and EDC are added together, they are stirred to make them uniformly mixed; the stirring time is 1-8 minutes; preferably, the stirring time is 1-5 minutes;
[0018] Or, first add NHS and then stir to mix evenly; the stirring time is 1-8 min; preferably, the stirring time is 1-5 min;
[0019] Then add EDC and stir to mix evenly; the stirring time is 1-8 minutes; preferably, the stirring time is 1-5 minutes.
[0020] 4. The preparation method according to item 3, wherein the stirring speed is 100-1000 rpm;
[0021] and / or, the temperature during stirring is 10-40°C.
[0022] 5. The preparation method described in any one of items 1 to 4, wherein the temperature during static soaking is 4-40°C.
[0023] 6. The preparation method according to any one of items 1 to 5, wherein when the collagen and the cross-linking agent are uniformly mixed in the solution, the concentration of the collagen is 1-20 wt %;
[0024] and / or, NHS concentration is 0.1-2wt%;
[0025] And / or, the EDC concentration is 0.5-10 wt %.
[0026] 7. The preparation method according to any one of items 1 to 6, wherein the pre-crosslinked hydrogel mixture is immersed in the ethanol solvent while being stirred;
[0027] Preferably, the stirring speed is 10-500 rpm.
[0028] 8. The preparation method according to any one of items 1 to 7, further comprising the following steps after obtaining the completely cross-linked collagen hydrogel:
[0029] The completely cross-linked collagen hydrogel is subjected to treatments including granulation, purification, solid-liquid separation and sterilization to obtain collagen hydrogel particles.
[0030] 9. The preparation method described in item 8, wherein after granulation, the particle size D50 of the particles is 50-500 μm, and D90 is 50-600 μm.
[0031] 10. The preparation method according to item 8 or 9, wherein the purification method is dialysis;
[0032] Preferably, the dialysis time is 1-8 days;
[0033] Preferably, the collagen hydrogel is dialyzed in PBS buffer;
[0034] More preferably, the pH of the PBS buffer is 6-9.
[0035] 11. The preparation method according to any one of items 8 to 10, wherein the solid-liquid separation method is selected from any one or more of centrifugation, filtration, suction filtration, microfiltration, and sedimentation;
[0036] Preferably, the solid-liquid separation method is centrifugation;
[0037] Preferably, the centrifugal conditions include: a centrifugal speed of 5000-15000 rpm; and / or a centrifugal time of 5-30 min; and / or a centrifugal temperature of 4-40°C.
[0038] 12. The preparation method according to any one of items 1 to 11, wherein the collagen is selected from any one or more of type I collagen, type II collagen, type III collagen, type IV collagen, type V collagen, type VI collagen and type VII collagen;
[0039] Preferably, the collagen is natural collagen or recombinant collagen;
[0040] Preferably, the collagen is recombinant collagen;
[0041] More preferably, the collagen is type III recombinant collagen;
[0042] More preferably, the molecular weight of the type III recombinant collagen is 20-60 kDa, 30-60 kDa, 40-60 kDa, 50-60 kDa, 25-55 kDa, 25-45 kDa, 30-50 kDa, or 35-45 kDa.
[0043] 13. The preparation method according to any one of items 1 to 12, wherein after the pre-crosslinking is completed, the viscosity of the collagen solution is 0.1-10 Pa.s;
[0044] Preferably, after the pre-cross-linking, the viscosity of the collagen solution is 0.1-1Pa.s, 0.1-2Pa.s, 0.1-3Pa.s, 0.1-4Pa.s, 0.1-5Pa.s, 0.1-6Pa.s, 0.1-7Pa.s, 0.1-8Pa.s, 0.1-9.5Pa.s, 1-2Pa.s, 1-3Pa.s, 1-5Pa.s, 1-8Pa.s, 1-10Pa.s, 2-4Pa.s, 2-6Pa.s, 2-8Pa.s, 3-5Pa.s, 3-7Pa.s, 3-9Pa.s, 4-5Pa.s, 4-7Pa.s, 4-8Pa.s, 5-7Pa.s, 5-9Pa.s, 6-8Pa.s, 6-9.5Pa.s, 7-9.5Pa.s or 8-9.5Pa.s.
[0045] 14. The preparation method according to any one of items 1 to 13, wherein the viscosity of the completely cross-linked collagen hydrogel is 100-1000 Pa.s;
[0046] Preferably, the viscosity of the completely cross-linked collagen hydrogel is 100-200 Pa.s, 100-400 Pa.s, 100-600 Pa.s, 100-800 Pa.s, 200-300 Pa.s, 200-500 Pa.s, 200-800 Pa.s, 200-900 Pa.s, 300-800 Pa.s, 300-500 Pa.s, 400-600 Pa.s, 400-900 Pa.s, 500-700 Pa.s, 500-800 Pa.s, 600-700 Pa.s, 600-800 Pa.s, 600-900 Pa.s, 700-800 Pa.s or 700-900 Pa.s.
[0047] Effects of the Invention
[0048] When preparing collagen hydrogel, the present application uses a method of pre-crosslinking and then ethanol solvent aggregation, so that the crosslinking process of the collagen hydrogel occurs simultaneously in the pre-crosslinking and ethanol aggregation stages, and finally obtains a milky white collagen hydrogel instead of a transparent collagen hydrogel, so that the prepared collagen hydrogel has a concealing effect when used as a medical and aesthetic filler. In addition, the collagen hydrogel obtained in the present application has significantly excellent stability, so that it can exert its filling and concealing effects for a long time in practical applications. BRIEF DESCRIPTION OF THE DRAWINGS
[0049] Figure 1 .Flow chart of the method of Example 1.
[0050] Figure 2 .The product morphology obtained in step S6 of Example 1.
[0051] Figure 3 . Flow chart of the method of Example 2.
[0052] Figure 4 .The product morphology obtained in step S7 of Example 2.
[0053] Figure 5 . Flow chart of the method of Example 3.
[0054] Figure 6 .The product morphology obtained in step S7 of Example 3.
[0055] Figure 7 .The morphology of the product obtained after ethanol aggregation in step S4 of Example 7.
[0056] Figure 8 .The morphology of the product obtained after ethanol aggregation in step S4 of Example 8.
[0057] Fig. 9 .Product morphology obtained after ethanol aggregation in step S4 in Example 9 and Comparative Example 1.
[0058] Fig.10 .Product morphology obtained after ethanol aggregation in step S4 of Example 10, Example 11 and Example 2. Specific implementation methods
[0060] It should be noted that certain words are used in the specification and claims to refer to specific components. Those skilled in the art should understand that technicians may use different nouns to refer to the same component. This specification and claims do not use the difference in nouns as a way to distinguish components, but use the difference in components' functions as the criterion for distinction.
[0061] As mentioned throughout the specification and claims, "including" or "comprising" is an open term and should be interpreted as "including but not limited to". The subsequent description of the specification is a preferred embodiment of the present application, but the description is for the purpose of the general principles of the specification and is not intended to limit the scope of the present application. The scope of protection of the present application shall be determined by the attached claims. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by ordinary technicians in the field to which the present disclosure belongs.
[0062] It should be understood that the embodiments of the present application described herein include "consisting of" and / or "consisting essentially of" embodiments. References to "about" a value or parameter herein include (and describe) variations to the value or parameter itself. For example, a description referring to "about X" includes a description of "X".
[0063] As used herein, reference to a "not" value or parameter generally means and describes an "except" value or parameter. For example, the method is not used to treat cancer type X, meaning that the method is used to treat cancers other than type X.
[0064] As used herein, the term "about XY" has the same meaning as "about X to about Y."
[0065] As used herein and in the appended claims, the singular forms "a", "an", and "the" include plural referents unless the context clearly dictates otherwise. It should also be noted that the claims may be drafted to exclude any optional elements. This statement is therefore intended to serve as antecedent basis for the use of exclusive terminology such as "only", "only" and the like in connection with the recitation of claim elements, or the use of a limitation of "no".
[0066] As used herein, the term "and / or" in phrases such as "A and / or B" is intended to include both A and B; A or B; A (alone); and B (alone). Similarly, as used herein, the term "and / or" in phrases such as "A, B, and / or C" is intended to include each of the following embodiments: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).
[0067] The present application provides a method for preparing a collagen hydrogel, comprising the following steps:
[0068] Mixing the collagen and the cross-linking agent evenly in the solution to obtain a pre-cross-linked hydrogel mixture;
[0069] The pre-crosslinked hydrogel mixture is immersed in an ethanol solvent and mixed evenly, and then allowed to stand and soak for at least 2 hours to obtain a completely crosslinked collagen hydrogel;
[0070] The cross-linking agents are N-hydroxysuccinimide (NHS) and 1-ethyl-(3-dimethylaminopropyl)carbodiimide (EDC);
[0071] The ethanol solvent is ethanol or an ethanol solution comprising ethanol and water, and the volume proportion of ethanol in the ethanol solution is 70-99.99 Vol.%.
[0072] The present application does not limit the source and type of collagen; as understood by those skilled in the art, any collagen can be used as a raw material for implementing the preparation method of the present application. In some embodiments, the collagen is naturally occurring and unmodified. In some embodiments, the collagen is artificially modified and non-natural. In some embodiments, the collagen is any combination of artificially modified collagen and naturally occurring collagen.
[0073] In some embodiments, the collagen is from an animal. In some embodiments, the animal is selected from any one or more of pigs, cows, donkeys, fish and chickens. In some embodiments, the collagen is from human collagen.
[0074] In some embodiments, the artificially modified collagen is obtained by modification or genetic recombination. In some embodiments, the modification is selected from any one or more of chemical modification and biological modification. In some embodiments, the chemical modification may be, for example, esterification of the hydroxyl groups on the amino acid side chains of collagen, and connection of new molecular structures through ester bonds. The molecular structure is selected from any one or more of cross-linkable groups or other functional groups including acyl, amino, sulfhydryl, carboxyl, etc. that participate in the formation of ester bonds. In some embodiments, the biological modification includes hydroxylation and glycosylation; in some embodiments, the biological modification is completed with the assistance of enzymes; for example, glycosylation modification is completed by catalysis of galactosyltransferase and glucosyltransferase to connect glycosyl groups to 5-hydroxylysine residues. In some embodiments, recombinant collagen is obtained by transducing the gene encoding collagen into the host cell and culturing the host cell. The gene encoding collagen is transduced into the host cell by any available method; for example, by introducing a recombinant plasmid containing a gene sequence encoding collagen; the host cell may be, for example, Pichia pastoris, Escherichia coli, etc. In an exemplary embodiment of the present application, the recombinant collagen is a recombinant collagen expressed by a Pichia pastoris system.
[0075] In some embodiments, the collagen is selected from any one or more of the group consisting of type I collagen, type II collagen, type III collagen, type IV collagen, type V collagen, type VI collagen, type VII collagen, and type XI collagen. In a specific embodiment, the collagen is type III collagen; in a specific embodiment, the collagen is recombinant type III collagen.
[0076] In some embodiments, the collagen is obtained commercially; in some embodiments, the collagen is extracted from animals; in some embodiments, the collagen is a modified, modified or recombinant collagen obtained by physically, chemically or biologically modifying the collagen. In an exemplary embodiment of the present application, the collagen is a commercially available recombinant type III collagen, for example, purchased from Shanxi Jinbo Biopharmaceutical Co., Ltd., or Xi'an Juzi Bio Co., Ltd., or Jiangshan Juyuan Bio Co., Ltd., or Jiangsu Chuangjian Bio Co., Ltd., or produced by the company itself.
[0077] In some embodiments, the molecular weight of collagen is 20-60kDa, 30-60kDa, 40-60kDa, 50-60kDa, 25-55kDa, 25-45kDa, 30-50kDa, 35-45kDa or any molecular weight range in the range of 20-60kDa. In a specific embodiment, the molecular weight of collagen is 20kDa, 30kDa, 40kDa, 50kDa, 60kDa, 25kDa, 35kDa, 45kDa or any molecular weight in the range of 20-60kDa.
[0078] In the present application, the process of "mixing collagen and cross-linking agent evenly in solution" can achieve pre-cross-linking of collagen, that is, the collagen at this time is not completely cross-linked; the pre-cross-linked collagen is transparent and viscous. When the pre-cross-linked collagen is mixed and soaked in an ethanol solvent, the collagen is completely cross-linked by standing and soaking. Exemplarily, when the collagen is type III collagen, the collagen hydrogel obtained after complete cross-linking is milky white; when the collagen hydrogel is used as a filler in the field of medical beauty, it has a significantly excellent concealing effect on pigments (such as eye melanin).
[0079] In this application, the degree of cross-linking of collagen is determined by measuring the viscosity of the collagen solution; specifically, the viscosity is measured according to "Pharmacopoeia Part IV - General Chapter 0633: Viscosity Determination Method, Method 3". As used herein, "complete cross-linking" is defined as complete cross-linking of the collagen when the viscosity of the collagen solution is 100-1000 Pa.s. In some embodiments, when the collagen is completely cross-linked, the viscosity of the collagen solution is any viscosity range within the range of 100-200 Pa.s, 100-400 Pa.s, 100-600 Pa.s, 100-800 Pa.s, 200-300 Pa.s, 200-500 Pa.s, 200-800 Pa.s, 200-900 Pa.s, 300-800 Pa.s, 300-500 Pa.s, 400-600 Pa.s, 400-900 Pa.s, 500-700 Pa.s, 500-800 Pa.s, 600-700 Pa.s, 600-800 Pa.s, 600-900 Pa.s, 700-800 Pa.s, 700-900 Pa.s or 100-1000 Pa.s. In some embodiments, when the collagen is completely cross-linked, the viscosity of the collagen solution is 100 Pa.s, 150 Pa.s, 200 Pa.s, 250 Pa.s, 300 Pa.s, 350 Pa.s, 400 Pa.s, 450 Pa.s, 500 Pa.s, 550 Pa.s, 600 Pa.s, 650 Pa.s, 700 Pa.s, 750 Pa.s, 800 Pa.s, 850 Pa.s, 900 Pa.s, 950 Pa.s, 1000 Pa.s or any viscosity in the range of 100-1000 Pa.s.
[0080] After the pre-crosslinking is completed, the viscosity of the collagen solution is 0.1-10 Pa.s. In some embodiments, after the pre-crosslinking is completed, the viscosity of the collagen solution is 0.1-0.5 Pa.s, 0.1-1 Pa.s, 0.1-2 Pa.s, 0.1-3 Pa.s, 0.1-4 Pa.s, 0.1-5 Pa.s, 0.1-6 Pa.s, 0.1-7 Pa.s, 0.1-8 Pa.s, 0.1-9.5 Pa.s, 1-2 Pa.s, 1-3 Pa.s, 1-5 Pa.s, 1-8 Pa.s .s, 1-10Pa.s, 2-4Pa.s, 2-6Pa.s, 2-8Pa.s, 3-5Pa.s, 3-7Pa.s, 3-9Pa.s, 4-5Pa.s, 4-7Pa.s, 4-8Pa.s, 5-7Pa.s, 5-9Pa.s, 6-8Pa.s, 6-9.5Pa.s, 7-9.5Pa.s, 8-9.5Pa.s or any viscosity range within the range of 0.1-10Pa.s. In some embodiments, after pre-cross-linking, the viscosity of the collagen solution is 0.1 Pa.s, 0.4 Pa.s, 0.8 Pa.s, 1 Pa.s, 1.5 Pa.s, 2 Pa.s, 2.5 Pa.s, 3 Pa.s, 3.5 Pa.s, 4 Pa.s, 5 Pa.s, 5.5 Pa.s, 6 Pa.s, 6.5 Pa.s, 7 Pa.s, 7.5 Pa.s, 8 Pa.s, 8.5 Pa.s, 9 Pa.s, 9.5 Pa.s, 10 Pa.s or any viscosity in the range of 0.1-10 Pa.s.
[0081] In some embodiments, the cross-linking agent is N-hydroxysuccinimide (NHS) and 1-ethyl-(3-dimethylaminopropyl) carbodiimide (EDC). In some embodiments, the cross-linking agents NHS and EDC are added at the same time and mixed with collagen. In some embodiments, NHS is added first and mixed evenly and then EDC is added to mix evenly. At the same time, the application finds that due to the short mixing time during pre-cross-linking, and only one cross-linking agent is added in the cross-linking stage, for example, only EDC is added or only NHS is added, it is difficult to achieve the desired cross-linking result, and the formed hydrogel is easy to further decompose in the aqueous solution, and after standing and soaking in an ethanol solvent, a shaped collagen hydrogel cannot be obtained. In addition, due to the short mixing time during pre-cross-linking, and when NHS is added after EDC is added to mix evenly in the cross-linking stage, it is also difficult to achieve the desired cross-linking result, and the formed hydrogel is easy to further decompose in the aqueous solution, and after standing and soaking in an ethanol solvent, a shaped collagen hydrogel cannot be obtained.
[0082] In some embodiments, when NHS and / or EDC are added, stirring is performed to make the mixture uniform; the stirring time is 1-3 min, 1-4 min, 1-5 min, 1-6 min, 1-7 min, 1-8 min, 2-5 min, 2-8 min, 3-5 min, 3-8 min, 4-5 min, 4-7 min or any time range within the range of 1-8 min; in some preferred embodiments, the stirring time is 1-5 min, 1-2 min, 1-3 min, 1-4 min, 2-3 min, 2-4 min, 3-4 min, 3-5 min or any time range within the range of 1-5 min. In a specific embodiment, the stirring time is 1 min, 1.5 min, 2 min, 2.5 min, 3 min, 3.5 min, 4 min, 4.5 min, 5 min, 6 min, 7 min, 8 min or any time within the range of 1-8 min.
[0083] In the present application, the pre-crosslinking time has a great influence on the viscosity of the final product. As the pre-crosslinking time increases, the viscosity of the final product increases. Exemplary data show the dynamic viscosity of the products of Examples 2 and 10 to 13. Among them, if the pre-crosslinking time is too short, as shown in Example 10, the degree of crosslinking of the collagen hydrogel is not enough after pre-crosslinking, then the product decomposes during the dialysis process after pre-crosslinking, and it is difficult to obtain a solid collagen hydrogel. However, it is not recommended to have a too long crosslinking time. For example, in Example 11, a milky white precipitate cannot be obtained in the end (refer to Fig.10 ). One of the uses of the collagen hydrogel prepared in the present application is as a medical cosmetic filler. Compared with the transparent collagen hydrogel, the milky white collagen hydrogel obviously has a better concealing effect. Therefore, in the present application, it is necessary to select an appropriate pre-crosslinking time. This makes the prepared collagen hydrogel have an appropriate viscosity and be milky white.
[0084] The present application has found that when the pre-crosslinked collagen is soaked in an ethanol solvent, the specific selection of the ethanol solvent has an effect on the crosslinking of the collagen. When the ethanol solvent is selected as ethanol or a 70-99.99Vol% concentration ethanol solution, aggregated milky white crosslinked collagen can be obtained after soaking in the ethanol solvent. When the ethanol solvent is selected as an ethanol solution with an ethanol concentration lower than 70Vol.%, lower than 60Vol.%, lower than 50Vol.%, lower than 40Vol.%, lower than 30Vol.%, lower than 20Vol.%, lower than 10Vol.%, for example, 10Vol.%, 20Vol.%, 40Vol.% or 60Vol.%, it is difficult to obtain aggregated milky white crosslinked collagen when the ethanol solvent is soaked and precipitated, and the obtained collagen is dispersed and non-aggregated. In some embodiments, the volume percentage of ethanol in the ethanol solution is 70-99.99 Vol.%, 80-99.99 Vol.%, 85-99.99 Vol.%, 88-99.99 Vol.%, 90-99.99 Vol.%, 95-99.99 Vol.%, 98-99.99 Vol.% or any volume percentage range within the range of 70-99.99 Vol.%; in a specific embodiment, In the example, the volume percentage of ethanol in the ethanol solution is 70 Vol.%, 75 Vol.%, 80 Vol.%, 82 Vol.%, 85 Vol.%, 88 Vol.%, 90 Vol.%, 92 Vol.%, 95 Vol.%, 96 Vol.%, 97 Vol.%, 98 Vol.%, 99 Vol.%, 99.99 Vol.% or any volume percentage in the range of 70-99.99 Vol.%.
[0085] The concentration of ethanol only affects the stability of the product in aqueous solution. When the concentration of ethanol is too low, the product is easy to decompose in aqueous solution, and the obtained product is not a solid collagen hydrogel that is aggregated together; instead, it is a loose, dispersed, and non-aggregated product. This product cannot be used as a medical and cosmetic filler; this application exemplarily proves through Examples 4 to 8 that ethanol solvent aggregation is the above effect of ethanol solvent on product preparation.
[0086] Among them, "Vol%" means the volume percentage of ethanol in the ethanol solvent. For example, "75Vol% ethanol solution" means: anhydrous ethanol and water are mixed in a volume ratio of 75:25, and the resulting product is 75Vol% ethanol solution.
[0087] The process of "mixing collagen and cross-linking agent uniformly in the solution", wherein the solvent in the solution is selected from water, acid or alkali; those skilled in the art should understand that, according to the solubility characteristics of collagen, a suitable solvent can be selected to dissolve collagen.
[0088] In some embodiments, the solvent for dissolving collagen is water; the collagen is water-soluble. In some embodiments, by mass percentage, when the collagen and the cross-linking agent are mixed uniformly in the solution, the collagen concentration is 1-20wt%; in some embodiments, the collagen concentration is 1-5wt%, 3-9wt%, 8-16wt%, 12-19wt%, 15-20wt% or any range within the range of 1-20wt%; in a specific embodiment, by mass percentage, when the collagen and the cross-linking agent are mixed uniformly in the solution, the collagen concentration is 1wt%, 2wt%, 3wt%, 4wt%, 5wt%, 6wt%, 7wt%, 8wt%, 9wt%, 10wt%, 11wt%, 12wt%, 13wt%, 14wt%, 15wt%, 16wt%, 17wt%, 18wt%, 19wt%, 20wt% or any concentration within the range of 1-20wt%.
[0089] In some embodiments, when the collagen and the cross-linking agent are uniformly mixed in the solution and the cross-linking agent is NHS, the concentration of NHS is 0.1-2wt% by mass; in some embodiments, the concentration of NHS is 0.1-0.5wt%, 0.3-0.9wt%, 0.8-1.6wt%, 1.2-1.9wt%, 1.5-2.0wt% or any range within the range of 0.1-2.0wt%; in a specific embodiment, the concentration of NHS is 0.1wt%, 0.25wt%, 0.4wt%, 0.65wt%, 0.86wt%, 0.97wt%, 1.08wt%, 1.29wt%, 1.40wt%, 1.51wt%, 1.68wt%, 1.84wt%, 1.93wt%, 2.0wt% or any concentration within the range of 0.1-2.0wt%.
[0090] In some embodiments, when the collagen and the cross-linking agent are uniformly mixed in the solution and the cross-linking agent is EDC, the EDC concentration is 0.5-10wt% by mass; in some embodiments, the collagen concentration is 0.5-1wt%, 1-5wt%, 3-7wt%, 6-9wt%, 8-10wt% or any range within the range of 0.5-10wt%; in a specific embodiment, the EDC concentration is 0.5wt%, 1wt%, 2wt%, 3wt%, 4wt%, 5wt%, 6wt%, 7wt%, 8wt%, 9wt%, 10wt% or any concentration within the range of 0.5-10wt% by mass.
[0091] In some embodiments, when the collagen and the cross-linking agent are mixed uniformly in the solution, the collagen solution is first configured, and then the cross-linking agent is added. In some embodiments, when multiple cross-linking agents are added, one cross-linking agent is added first, and after mixing uniformly, the second cross-linking agent is added, and then mixed uniformly; until all types of cross-linking agents are added. In some embodiments, after adding the cross-linking agent, stirring is performed to achieve uniform mixing; in some embodiments, the stirring time is 1-30min; in some preferred embodiments, the stirring time is 2-8min; in some more preferred embodiments, the stirring time is 4-5min. In some embodiments, the stirring time is 1-5min, 3-11min, 8-16min, 12-19min, 18-25min, 23-28min, 27-30min or any time range within the range of 1-30min; in a specific embodiment, the stirring time is 1min, 4min, 9min, 13min, 17min, 22min, 25min, 29min or any time within the range of 1-30min. In some embodiments, the collagen and the cross-linking agent are stirred in the solution at a speed of 100-1000 rpm; in some embodiments, the stirring speed is 100-200 rpm, 150-300 rpm, 250-400 rpm, 350-500 rpm, 450-600 rpm, 550-700 rpm, 650-800 rpm, 750-900 rpm, 850-1000 rpm or any speed range within the range of 100-1000 rpm; in a specific embodiment, the stirring speed is 100 rpm, 400 rpm, 650 rpm, 850 rpm, 950 rpm, 1000 rpm or any speed range within the range of 100-1000 rpm. In some embodiments, the stirring temperature is 10-40°C; in some embodiments, the stirring temperature is 10-20°C, 15-25°C, 20-30°C, 25-35°C, 30-40°C or any temperature range within the range of 10-40°C; in a specific embodiment, the stirring temperature is 10°C, 15°C, 20°C, 25°C, 30°C, 35°C, 40°C or any temperature within the range of 10-40°C.
[0092] In some embodiments, when the pre-crosslinked hydrogel mixture is immersed in the ethanol solvent, stirring is performed. After the pre-crosslinked hydrogel mixture is completely immersed in the ethanol solvent, stirring is stopped. In some embodiments, the stirring speed is 10-500rpm; in some embodiments, the stirring speed is 10-50rpm, 40-100rpm, 90-150rpm, 150-240rpm, 230-320rpm, 310-400rpm, 350-480rpm, 450-500rpm or any speed range within the range of 10-500rpm; in a specific embodiment, the stirring speed is 10rpm, 30rpm, 80rpm, 110rpm, 140rpm, 210rpm, 280rpm, 350rpm, 380rpm, 420rpm, 500rpm or any speed range within the range of 10-500rpm.
[0093] In the present application, the process of standing and soaking is the stage in which the collagen hydrogel gradually changes from pre-crosslinking to fully crosslinking. In this process, the dynamic viscosity of the collagen hydrogel solution gradually changes from 0.1-10Pa.s to 100-1000Pa.s; the collagen hydrogel gradually changes into a more aggregated, milky white precipitate. Among them, the standing time has a significant effect on the final product characteristics. The standing time is too short, such as the exemplary comparative example 1, then the obtained collagen hydrogel is still transparent. Therefore, sufficient standing time is guaranteed to make the collagen hydrogel more fully crosslinked.
[0094] In some embodiments, the time of standing and soaking is at least 2h, at least 3h, at least 4h, at least 5h, at least 6h, at least 7h, at least 8h; in some preferred embodiments, the time of standing and soaking is 2-8h. In some embodiments, the time of standing and soaking is 2-4h, 3.5-6h, 6-7h, 6.5-8h or any time range within the range of 2-8h; in a specific embodiment, the time of standing and soaking is 2h, 2.5h, 3h, 5h, 6.5h, 7.8h or any time within the range of 2-8h. In some embodiments, the temperature during static soaking is 4-40°C; in some embodiments, the temperature during static soaking is 4-10°C, 8-15°C, 12-20°C, 15-25°C, 22-36°C, 35-40°C or any temperature range within the range of 4-40°C; in a specific embodiment, the temperature during static soaking is 4°C, 10°C, 16°C, 22°C, 28°C, 32°C, 38°C or any temperature within the range of 4-40°C.
[0095] In some embodiments, after obtaining the completely cross-linked collagen hydrogel, the following steps are further included:
[0096] The completely cross-linked collagen hydrogel is subjected to treatments including granulation, purification, solid-liquid separation and sterilization to obtain collagen hydrogel particles.
[0097] It should be noted that the processing order of "granulation", "purification" and "solid-liquid separation" is not limited in this application, and the processing order of the above steps has no significant effect on the final performance of the obtained collagen hydrogel. In some embodiments, granulation, purification, solid-liquid separation and sterilization are carried out in sequence; in some embodiments, purification, granulation, solid-liquid separation and sterilization are carried out in sequence; in some embodiments, purification, solid-liquid separation, granulation and sterilization are carried out in sequence; in some embodiments, solid-liquid separation, purification, granulation and sterilization are carried out in sequence; in some embodiments, solid-liquid separation, granulation, purification and sterilization are carried out in sequence.
[0098] As known to those skilled in the art, the present application does not limit the specific method of granulation; the available granulation method can be, for example, granulation with a granulator, rolling granulation, granulation with a granulator, spray drying granulation, fluidized bed granulation, spherical granulation, extrusion granulation, freeze-drying granulation, or any two or more of the above methods combined for granulation; after the final granulation, the particle size of the particles has a D50 of 50-500 μm and a D90 of 50-600 μm. In some preferred embodiments, granulation is performed with a granulator. For the determination of the particle size after granulation, the third method "light scattering method" wet method in the "0982 Particle Size and Particle Size Distribution Determination Method" of the four general rules of the Pharmacopoeia of the People's Republic of China (2020 edition) is used for determination.
[0099] In some embodiments, the purification method is dialysis; in some embodiments, the dialysis is performed in a buffer; preferably, the buffer is a PBS buffer. In some embodiments, the pH of the PBS buffer is 6-9; in some embodiments, the pH of the PBS buffer is 6-7, 7-8, 8-9, or any pH range within the range of 6-9; in a specific embodiment, the pH of the PBS buffer is 6, 6.5, 7, 7.5, 8, 8.5, 9, or any pH within the range of 6-9.
[0100] In some embodiments, the solid-liquid separation method may be, for example, any one or more of centrifugation, filtration, suction filtration, microfiltration, and sedimentation; in some embodiments, the solid-liquid separation method is centrifugation. In some embodiments, the centrifugal conditions include: a centrifugal speed of 5000-15000 rpm; in some embodiments, the centrifugal speed is 5000-7000 rpm, 6000-8000 rpm, 7500-10000 rpm, 9000-12000 rpm, 10500-12500 rpm, 12000-14500 rpm, 13000-15000 rpm or any speed range within the range of 5000-15000 rpm; in a specific embodiment, the centrifugal speed is 5000 rpm, 6500 rpm, 8000 rpm, 9500 rpm, 11000 rpm, 12500 rpm, 13600 rpm, 14200 rpm, 15000 rpm or any speed range within the range of 5000-15000 rpm. In some embodiments, the centrifugation conditions include: centrifugation time is 5-30 min; in some embodiments, the centrifugation time is 5-12 min, 10-18 min, 15-26 min, 23-28 min, 27-30 min or any time range within the range of 5-30 min; in a specific embodiment, the centrifugation time is 5 min, 11 min, 18 min, 21 min, 25 min, 28 min, 30 min or any time within the range of 5-30 min. In some embodiments, the centrifugation conditions include: a centrifugation temperature of 4-40°C; in some embodiments, the centrifugation temperature is 4-12°C, 10-18°C, 15-26°C, 23-28°C, 27-32°C, 30-35°C, 33-38°C, 36-40°C or any temperature range within the range of 4-40°C; in a specific embodiment, the centrifugation temperature is 4°C, 6°C, 9°C, 14°C, 17°C, 21°C, 24°C, 28°C, 32°C, 35°C, 38°C or any temperature within the range of 4-40°C.
[0101] According to the method of the present application, the collagen hydrogel finally obtained by pre-crosslinking and then aggregation and crosslinking with an ethanol reagent is milky white and has remarkably excellent stability. After the obtained collagen hydrogel is aged at 40°C for 66 days, it is still milky white and transparent; the change rate of its osmotic pressure molar concentration is less than 0.7%, or even less than 0.35%; the loss rate of its collagen content is not higher than 1.13%, generally not higher than 0.25%, or even no loss; and the dynamic viscosity has only a slight change, and its change rate is no more than 1.5%. It can be seen that the collagen hydrogel obtained by the method of the present application has remarkably excellent stability, and after being used for medical and aesthetic filling, it can play its filling and concealing effects for a long time. Example
[0102] The specific embodiments of the present application will be described in more detail below with reference to the accompanying drawings. Although the specific embodiments of the present application are shown in the accompanying drawings, it should be understood that the present application can be implemented in various forms and should not be limited by the embodiments set forth herein. On the contrary, these embodiments are provided in order to enable a more thorough understanding of the present application and to fully convey the scope of the present application to those skilled in the art.
[0103] Raw material information:
[0104] The EDC used in this application has the Chinese name 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (CAS: 25952-53-8);
[0105] The English name is 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimidehydrochloride;
[0106] The NHS used in this application has the Chinese name N-hydroxysuccinimide (CAS: 6066-82-6);
[0107] The English name is N-Hydroxysuccinimide; 1-Hydroxy-2,5-pyrrolidinedione.
[0108] Recombinant type III collagen: purchased from Jiangshan Juyuan Biological Co., Ltd., with a molecular weight of 30-50kD.
[0109] Anhydrous ethanol (CAS: 64-17-5).
[0110] PBS solution: In 1L of water for injection, add 8.5g of sodium chloride, 1.32g of disodium hydrogen phosphate, and 0.06g of sodium dihydrogen phosphate to prepare a PBS solution; alternatively, PBS solution: 1000g of water for injection, 8.5g of sodium chloride, 1.32g of disodium hydrogen phosphate, and 0.06g of sodium dihydrogen phosphate.
[0111] Example
[0112] Example 1
[0113] Reference Figure 1 The preparation method of the collagen hydrogel of this embodiment is as follows:
[0114] Step S1. Prepare collagen solution: weigh 1g of recombinant type III collagen and 57g of water for injection to prepare collagen solution. After adding the cross-linking agent, the concentration of collagen is 1wt%.
[0115] Step S2. NHS cross-linking: Weigh 2 g NHS and dissolve it in 20 g water for injection to obtain NHS solution; pour the NHS solution into the collagen solution obtained in step S1 and stir at a stirring speed of 1000 rpm, a temperature of 10° C., and a stirring time of 1 min. After the cross-linking agent is finally added, the NHS concentration is 2 wt%.
[0116] Step S3. EDC cross-linking: weigh 10 g of EDC, dissolve it in 10 g of water for injection, and obtain an EDC solution (EDC accounts for 10 wt% of the total amount); pour the EDC solution into the collagen solution obtained in step S1, and stir it at a stirring speed of 1000 rpm, a temperature of 10° C., and a stirring time of 1 min.
[0117] The viscosity of the hydrogel solution obtained after step S3 (the dynamic viscosity is measured with reference to the third method of "Pharmacopoeia General Rules 0633 Viscosity Determination Method of Part IV") is 0.9 Pa.s.
[0118] Step S4. Ethanol aggregation: Pour the cross-linked material from step S3 into 1L of anhydrous ethanol for soaking, stirring during the pouring process at a speed of 10 rpm. Stop stirring after the pouring is completed, at which time the collagen is not completely cross-linked. Then soak and stand at a temperature of 4°C for 2 hours to achieve complete cross-linking.
[0119] Step S5. Dialysis: prepare a PBS solution of pH 6 (in 1 L of water for injection, add 8.5 g of sodium chloride, 1.32 g of disodium hydrogen phosphate, and 0.06 g of sodium dihydrogen phosphate to prepare a PBS solution), then immerse the hydrogel formed in step S4 in the prepared PBS solution and dialyze for 3 days; replace the PBS solution three times a day.
[0120] Step S6. Granulation and centrifugation: Pour the hydrogel dialyzed in step S5 into the granulation equipment for granulation, so that the particle size range of the obtained collagen hydrogel is D50: 50-500μm, D90: 50-600μm (refer to the third method "Light scattering method" wet method in the "0982 Particle size and particle size distribution determination method" of the fourth general rule of the "Pharmacopoeia of the People's Republic of China" (2020 edition) for determination). After the granulation is completed, pour the material into a centrifuge cup and balance it for centrifugation. The centrifugal speed is 10000rpm, the centrifugal temperature is 40°C, and the centrifugal time is 15min. The product is then obtained, which is specifically as follows Figure 2 As shown, a milky white collagen hydrogel was obtained.
[0121] Step S7. Filling: After the centrifugation, remove the supernatant and mix well, then pour it into the filling machine. The filling specification is 0.5mL / tube.
[0122] Step S8. Sterilization: The filled product is sterilized by moist heat at a temperature of 120° C. for 30 minutes. After sterilization, the target product is obtained: milky white collagen hydrogel.
[0123] Example 2
[0124] Reference Figure 3 The preparation method of the collagen hydrogel of this embodiment is as follows:
[0125] Step S1. Prepare collagen solution: weigh 10g recombinant type III collagen and 69g water for injection to prepare collagen solution. After adding the cross-linking agent, the concentration of collagen is 10wt%.
[0126] Step S2. NHS cross-linking: weigh 1g NHS and dissolve it in 10g water for injection to obtain NHS solution; pour the NHS solution into the collagen solution obtained in step S1 and stir at a stirring speed of 500rpm, a temperature of 40°C, and a stirring time of 3min. After the cross-linking agent is finally added, the NHS concentration is 1wt%.
[0127] Step S3. EDC cross-linking: weigh 5 g of EDC and dissolve it in 5 g of water for injection to obtain an EDC solution (EDC accounts for 5 wt% of the total amount); pour the EDC solution into the collagen solution prepared in step S1 and stir at a stirring speed of 500 rpm, a temperature of 40° C., and a stirring time of 3 min.
[0128] The viscosity of the hydrogel solution obtained after step S3 (the dynamic viscosity is measured with reference to the third method of "Pharmacopoeia General Rules 0633 Viscosity Determination Method of Part IV") is 4.7 Pa.s.
[0129] Step S4. Ethanol aggregation: Pour the cross-linked material from step S3 into 1L of anhydrous ethanol for soaking, stirring at 300rpm, and stop stirring after pouring, at which time the collagen is not completely cross-linked. Then soak and stand at 4°C for 4h to achieve complete cross-linking.
[0130] Step S5. Granulation: Pour the hydrogel soaked in step S4 into a granulation equipment for granulation, so that the particle size range of the obtained collagen hydrogel is D50: 50-500 μm, D90: 50-600 μm (refer to the third method "light scattering method" wet method in the fourth general rule "0982 Particle size and particle size distribution determination method" of the "Pharmacopoeia of the People's Republic of China" (2020 edition)).
[0131] Step S6. Dialysis: prepare a PBS solution of pH 6 (in 1 L of water for injection, add 8.5 g of sodium chloride, 1.32 g of disodium hydrogen phosphate, and 0.06 g of sodium dihydrogen phosphate to prepare a PBS solution), and then dialyze the hydrogel particles formed in step S5 in the prepared PBS solution for 5 days; replace the PBS solution three times a day.
[0132] Step S7. Centrifugation: Pour the dialyzed material from step S6 into a centrifuge cup and centrifuge at a centrifugal speed of 11000 rpm, a centrifugal temperature of 40°C, and a centrifugal time of 20 min. Figure 4 As shown, a milky white collagen hydrogel was obtained.
[0133] Step S8. Filling: After the centrifugation, remove the supernatant and mix well, then pour it into the filling machine. The filling specification is 0.5mL / tube.
[0134] Step S9. Sterilization: The filled product is sterilized by moist heat at a temperature of 120° C. for 30 minutes. After sterilization, the target product is obtained: milky white collagen hydrogel.
[0135] Example 3
[0136] Reference Figure 5 The preparation method of the collagen hydrogel of this embodiment is as follows:
[0137] Step S1. Prepare collagen solution: weigh 20g recombinant type III collagen and 77.9g water for injection to prepare collagen solution. After adding the cross-linking agent, the concentration of collagen is 20wt%.
[0138] Step S2. NHS cross-linking: Weigh 0.1 g NHS and dissolve it in 1.0 g water for injection to obtain NHS solution; pour the NHS solution into the collagen solution obtained in step S1 and stir at a stirring speed of 100 rpm, a temperature of 10° C., and a stirring time of 5 min. After the cross-linking agent is finally added, the NHS concentration is 0.1 wt%.
[0139] Step S3. EDC cross-linking: weigh 0.5 g EDC, dissolve it in 0.5 g water for injection, and obtain an EDC solution (EDC accounts for 0.5 wt% of the total amount); pour the EDC solution into the collagen solution obtained in step S1, and stir it at a stirring speed of 100 rpm, a temperature of 10° C., and a stirring time of 5 min.
[0140] The viscosity of the hydrogel solution obtained after step S3 (the dynamic viscosity is measured with reference to the third method of "Pharmacopoeia General Rules 0633 Viscosity Determination Method of Part IV") is 8.4 Pa.s.
[0141] Step S4. Ethanol aggregation: Pour the cross-linked material from step S3 into 1L of anhydrous ethanol for soaking, stirring during the pouring process at a speed of 500rpm. Stirring is stopped after the pouring is completed, at which time the collagen is not completely cross-linked. Then, soak and stand at a temperature of 4°C for 8 hours to achieve complete cross-linking.
[0142] Step S5. Dialysis: Prepare a PBS solution of pH 6 (in 1 L of water for injection, add 8.5 g of sodium chloride, 1.32 g of disodium hydrogen phosphate, and 0.06 g of sodium dihydrogen phosphate to prepare a PBS solution), then soak the hydrogel formed in step S4 in the prepared PBS solution and dialyze for 5 days; replace the PBS solution three times a day.
[0143] Step S6. Centrifugation: Pour the hydrogel dialyzed in step S5 into a centrifuge cup and centrifuge at a centrifugal speed of 15000 rpm, a centrifugal temperature of 4° C., and a centrifugal time of 5 min.
[0144] Step S7. Granulation: Remove the supernatant from the hydrogel after centrifugation in step S6, pour it into a granulation device for granulation, so that the particle size range of the obtained collagen hydrogel is D50: 50-500μm, D90: 50-600μm (refer to the third method "light scattering method" wet method in the fourth general rule "0982 Particle size and particle size distribution determination method" of the "Pharmacopoeia of the People's Republic of China" (2020 edition)). Then the product is obtained, which is as follows Figure 6 As shown, a milky white collagen hydrogel was obtained.
[0145] Step S8. Filling: Pour the granules after granulation into the filling machine, and the filling specification is 0.5 mL / tube.
[0146] Step S9. Sterilization: The filled product is sterilized by moist heat at a temperature of 120° C. for 30 minutes. After sterilization, the target product is obtained: milky white collagen hydrogel.
[0147] Embodiment 4 to Embodiment 8
[0148] The only difference between Examples 4 to 8 and Example 2 is that when ethanol is aggregated, the ethanol solvent is selected differently. The ethanol solvent in Examples 4 to 8 is an ethanol solution prepared by mixing ethanol and water; the volume proportion of ethanol in the ethanol solution in Examples 4 to 8 is different; see Table 1 for details.
[0149] Table 1 Selection of ethanol solvent in different implementation schemes
[0150]
[0151]
[0152] The morphology of the product obtained after ethanol aggregation in step S4 in the above embodiments was observed. It was found that the products obtained by the methods of Examples 4 to 7 were in a dispersed state after ethanol reagent precipitation, and did not aggregate into a milky white precipitate. Taking the morphology of the product obtained after ethanol aggregation in step S4 of Example 7 as an example, the product morphology diagrams of Examples 4 to 7 are given as examples. For details, please refer to Figure 7 .
[0153] The product obtained after ethanol aggregation in step S4 in Example 8 has the following morphology: Figure 8 As shown, a certain amount of milky white gel is formed, and the product morphology is relatively more stable and aggregated. However, it is also found that the product obtained after ethanol aggregation in step S4 of Example 8 has a relatively smaller amount of milky white gel than the product obtained after ethanol aggregation in step S4 of Example 2, so using anhydrous ethanol as the ethanol solvent has a better effect.
[0154] Example 9, Comparative Example 1
[0155] The difference between Example 9 and Comparative Example 1 and Example 2 is that when the material body after cross-linking in step S3 is poured into 1L of anhydrous ethanol for soaking in step S4, the soaking and standing time is different. In Example 9, the soaking and standing time is 2h. In Comparative Example 1, the soaking and standing time is 1h.
[0156] The morphology of the product obtained after ethanol aggregation in step S4 in the above embodiment was observed. It was found that the product obtained by the method of comparative example 1 had poor crosslinking effect after ethanol reagent precipitation, resulting in decomposition of the obtained product in aqueous solution and difficulty in obtaining a milky white precipitate. The specific results are shown in Fig. 9 The product obtained by the method of Example 9 has a good cross-linking effect after precipitation with ethanol reagent, and a large amount of obviously aggregated milky white collagen hydrogel is obtained; the specific results are shown in Fig. 9 .
[0157] Example 10 to Example 13
[0158] Compared with Example 2, Examples 10 to 13 are different only in that the crosslinking time of NHS crosslinking in step S2 and EDC crosslinking in step S3 is different. Specifically, in Example 10, the crosslinking time of NHS crosslinking in step S2 and EDC crosslinking in step S3 is 0.5 min; in Example 11, the crosslinking time of NHS crosslinking in step S2 and EDC crosslinking in step S3 is 8 min; in Example 12, the crosslinking time of NHS crosslinking in step S2 and EDC crosslinking in step S3 is 1 min; in Example 13, the crosslinking time of NHS crosslinking in step S2 and EDC crosslinking in step S3 is 5 min. The other steps are the same as in Example 2.
[0159] Among them, the collagen hydrogel was prepared by the method of Example 10, and the dynamic viscosity of the hydrogel solution obtained after step S3 (i.e., after the pre-crosslinking was completed) was 0.04 Pa.s (the dynamic viscosity was measured by referring to the "Pharmacopoeia General Rules of Part IV 0633 Viscosity Determination Method Third Method"). The collagen hydrogel was prepared by the method of Example 11, and the dynamic viscosity of the hydrogel solution obtained after step S3 (i.e., after the pre-crosslinking was completed) was 219 Pa.s.
[0160] The morphology of the product obtained after ethanol aggregation in step S4 in the above embodiment was observed. It was found that the product obtained by the method of Example 10 had a poor crosslinking effect after ethanol reagent precipitation. The reason was that the pre-crosslinking (i.e., NHS crosslinking in step S2 and EDC crosslinking in step S3) time was too short, so that even after ethanol aggregation, the obtained product was still easy to decompose in aqueous solution, and it was difficult to obtain a milky white precipitate; the specific results are shown in Fig.10 However, the product obtained by the method of Example 11 had a too long pre-crosslinking time (i.e., NHS crosslinking in step S2 and EDC crosslinking in step S3), so that a large amount of solid gel (non-milky white) was formed during the pre-crosslinking stage. Therefore, even after ethanol aggregation, the obtained product was still not a milky white collagen hydrogel; the specific results are shown in Fig.10 However, the method of Example 2 ultimately yields a large amount of milky white collagen hydrogel.
[0161] When the collagen hydrogel is prepared by the method of Example 12, the dynamic viscosity of the hydrogel solution obtained after step S3 (i.e., after the pre-crosslinking is completed) is 1.6Pa.s, and the dynamic viscosity of the final collagen hydrogel product is 211Pa.s, and the resulting collagen hydrogel is milky white and solid. When the collagen hydrogel is prepared by the method of Example 13, the dynamic viscosity of the hydrogel solution obtained after step S3 (i.e., after the pre-crosslinking is completed) is 9.4Pa.s, and the dynamic viscosity of the final collagen hydrogel product is 983Pa.s, and the resulting collagen hydrogel is also milky white and solid. The dynamic viscosity of the products of Examples 10-13 at different stages is shown in Table 4.
[0162] Embodiment 14
[0163] In this embodiment, EDC and NHS are added together during pre-crosslinking.
[0164] The preparation method of the collagen hydrogel of this embodiment is as follows:
[0165] Step S1. Prepare collagen solution: weigh 10g recombinant type III collagen and 74.6g water for injection to prepare collagen solution. After adding the cross-linking agent, the concentration of collagen is 10wt%.
[0166] Step S2. Cross-linking: Add 4.5g EDC and 0.9g NHS to 10g water for injection and stir until fully dissolved to obtain a cross-linking agent solution. Pour the prepared cross-linking agent solution into the collagen solution obtained in step S1 and stir at a stirring speed of 500rpm, a temperature of 40°C, and a stirring time of 5min. After the cross-linking agent is finally added, the concentration of NHS is 0.9wt% and the concentration of EDC is 4.5wt%.
[0167] Step S3. Ethanol aggregation: Pour the cross-linked material in step S3 into 1L of anhydrous ethanol for soaking, stirring during the pouring process at a speed of 300rpm. Stirring is stopped after the pouring is completed, at which time the collagen is not completely cross-linked. Then soak and stand at a temperature of 4°C for 4 hours to achieve complete cross-linking.
[0168] Step S4. Dialysis: Prepare a PBS solution of pH 6 (in 1 L of water for injection, add 8.5 g of sodium chloride, 1.32 g of disodium hydrogen phosphate, and 0.06 g of sodium dihydrogen phosphate to prepare a PBS solution), and then dialyze the hydrogel particles formed in step S5 in the prepared PBS solution for 5 days; replace the PBS solution three times a day.
[0169] Step S5. Granulation and centrifugation: Pour the hydrogel dialyzed in step S4 into a granulation device for granulation, so that the particle size range of the obtained collagen hydrogel is D50: 50-500μm, D90: 50-600μm. After granulation, pour the material into a centrifuge cup and centrifuge it at a balanced speed of 12000rpm, a centrifugal temperature of 4°C, and a centrifugal time of 20min. Remove the supernatant to obtain the target product.
[0170] Step S7. Filling: After the centrifugation, remove the supernatant and mix well, then pour it into the filling machine. The filling specification is 0.5mL / tube.
[0171] Step S8. Sterilization: The filled product is sterilized by moist heat at a temperature of 120° C. for 30 minutes. After sterilization, the target product is obtained: milky white collagen hydrogel.
[0172] Comparative Example 2
[0173] The main difference between this comparative example and Example 2 is that when preparing the collagen hydrogel in this comparative example, the step of aggregating with an ethanol reagent was not adopted. The details are as follows:
[0174] The preparation method of collagen hydrogel is as follows:
[0175] Step 1. Prepare collagen solution: weigh 10g recombinant type III collagen and 69g water for injection to prepare collagen solution. After adding the cross-linking agent, the collagen concentration is 10wt%.
[0176] Step 2. NHS cross-linking: Weigh 1g NHS and dissolve it in 10g water for injection to obtain NHS solution; pour the NHS solution into the collagen solution prepared in step 1 and stir at a stirring speed of 500rpm, a temperature of 40°C, and a stirring time of 5min. After the cross-linking agent is finally added, the NHS concentration is 1wt%.
[0177] Step 3. EDC cross-linking: weigh 5g EDC and dissolve it in 5g water for injection to obtain an EDC solution (EDC accounts for 5wt% of the total amount); pour the EDC solution into the collagen solution prepared in step 2 and stir it at a stirring speed of 500rpm, a temperature of 40°C, and a stirring time of 5min. Then, stand it at a temperature of 4°C for 4h to achieve complete cross-linking.
[0178] The subsequent steps of granulation, dialysis, centrifugation, filling and sterilization are the same as in Example 2.
[0179] It was found that the method of Comparative Example 2 obtained a transparent collagen hydrogel, but not the milky white collagen hydrogel required by the present application.
[0180] Performance Testing
[0181] 1. The final product obtained in Example 2 was subjected to the following tests, and the results are shown in Table 2. After accelerated aging at 40°C for 66 days, all indicators of the product had no significant difference from those before aging, so it can be judged that the thermal stability of the product is relatively good.
[0182] Table 2 Performance test results of the products in Example 2
[0183]
[0184] 2. The following performance tests were performed on the hydrogel products obtained in Examples 1 to 3 and Comparative Example 2. The results are shown in Table 3.
[0185] Table 3 Performance test results of the products of Examples 1 to 3 and Comparative Example 2
[0186]
[0187]
[0188] It can be seen from the results in Table 3 that the collagen hydrogel obtained in the present application has good stability. After being placed at a high temperature of 40°C for up to 66 days, its appearance, osmotic pressure, pH, collagen content and viscosity remain stable, which is significantly better than the product obtained in Comparative Example 2.
[0189] 3. The dynamic viscosity of the hydrogel solutions obtained in step S3 of Examples 10 to 13 and the dynamic viscosity of the final collagen hydrogel products were tested. The results are shown in Table 4.
[0190] Table 4 Dynamic viscosity of products of different embodiments
[0191]
[0192] From the results in Table 4, it can be seen that the pre-crosslinking time is relatively important for the final formation of the desired product. If the pre-crosslinking time is too short, such as in Example 10, the crosslinking degree is insufficient, and the product decomposes during the dialysis process after the pre-crosslinking, and it is difficult to obtain a solid collagen hydrogel. If the crosslinking time is too long, such as in Example 11, it is difficult to obtain a milky white precipitate, that is, Fig.10 As shown, a large amount of solid gel (non-milky white) is formed in the pre-crosslinking stage. As in Examples 2, 12 and 13, the pre-crosslinking time is more suitable within the range of 1-5 min, and a milky white collagen hydrogel with suitable viscosity can be obtained.
Claims
1. A method for preparing a collagen hydrogel, comprising the following steps: Mixing the collagen and the cross-linking agent evenly in the solution to obtain a pre-cross-linked hydrogel mixture; The pre-crosslinked hydrogel mixture is immersed in an ethanol solvent and mixed evenly, and then allowed to stand and soak for at least 2 hours to obtain a completely crosslinked collagen hydrogel; The cross-linking agents are N-hydroxysuccinimide (NHS) and 1-ethyl-(3-dimethylaminopropyl)carbodiimide (EDC); The ethanol solvent is ethanol or an ethanol solution comprising ethanol and water, wherein the volume proportion of ethanol in the ethanol solution is 70-99.99 Vol.%; Preferably, the volume percentage of ethanol in the ethanol solution is 80-99.99 Vol.%; Preferably, the ethanol solvent is ethanol; Preferably, the standing soaking time is 2-8 hours.
2. The preparation method according to claim 1, when the collagen and the cross-linking agent are mixed evenly, NHS and EDC are added together and then mixed evenly, or NHS is first added and mixed evenly and then EDC is added and mixed evenly.
3. The preparation method according to claim 2, after NHS and EDC are added together, they are stirred to make them uniformly mixed; the stirring time is 1-8 min; preferably, the stirring time is 1-5 min; Or, first add NHS and then stir to mix evenly; the stirring time is 1-8 min; preferably, the stirring time is 1-5 min; Then add EDC and stir to mix evenly; the stirring time is 1-8 minutes; preferably, the stirring time is 1-5 minutes.
4. The preparation method according to claim 3, wherein the stirring speed is 100-1000 rpm; and / or, the temperature during stirring is 10-40°C.
5. The preparation method according to any one of claims 1 to 4, wherein the temperature during static soaking is 4-40°C.
6. The preparation method according to any one of claims 1 to 5, wherein when the collagen and the cross-linking agent are uniformly mixed in the solution, the concentration of the collagen is 1-20 wt%; and / or, NHS concentration is 0.1-2wt%; And / or, the EDC concentration is 0.5-10 wt %.
7. The preparation method according to any one of claims 1 to 6, wherein the pre-crosslinked hydrogel mixture is immersed in the ethanol solvent while being stirred; Preferably, the stirring speed is 10-500 rpm.
8. The preparation method according to any one of claims 1 to 7, further comprising the following steps after obtaining the completely cross-linked collagen hydrogel: The completely cross-linked collagen hydrogel is subjected to treatments including granulation, purification, solid-liquid separation and sterilization to obtain collagen hydrogel particles. 9 . The preparation method according to claim 8 , wherein after the granulation, the particle size D50 of the particles is 50-500 μm, and the D90 is 50-600 μm.
10. The preparation method according to claim 8 or 9, wherein the purification method is dialysis; Preferably, the dialysis time is 1-8 days; Preferably, the collagen hydrogel is dialyzed in PBS buffer; More preferably, the pH of the PBS buffer is 6-9.
Citation Information
Cited By
Injectable microphase-separated hydrogel, preparation method therefor, and use thereof
WO2026138740A1
